NUR5213 Module 3 special population pharmacokinetics analysis example

Which Weight? How Obesity Changes Where Drugs Go and How Fast They Leave, Worked Through a 150-Kilogram Patient on Vancomycin

Student Name

American College of Education

NUR5213: Advanced Pharmacology for Health Educators

Module 3 Assignment

Instructor Name

March 21, 2028

Why Obesity Is a Special Population

Pharmacology courses usually name older adults, children, pregnant patients and people with kidney or liver disease as special populations. Obesity belongs on that list. In national survey data from 2017 to 2018, 42.4% of adults in the United States had obesity and 9.2% had severe obesity (Hales et al., 2020), yet most drugs were studied in trials that included few patients with severe obesity, and product labels often give doses in milligrams per kilogram without saying which kilogram. Hanley et al. (2010), reviewing the pharmacokinetics of drugs in obesity, concluded that data in obese patients do not exist for most drugs and that clinicians must reason from each drug's properties. At the composite 280-bed hospital where the author teaches nurses, a medication safety review found that 14% of patients with a body mass index above 40 had an admission weight that was stated by the patient or estimated rather than measured, and in two of those cases a weight-based drug had been dosed from a figure 20 kg off.

Volume of Distribution and the Loading Dose

Volume of distribution describes how widely a drug spreads through the body relative to its concentration in blood. It determines the loading dose: to reach a target concentration quickly, the dose must fill the volume the drug occupies. Obesity changes body composition. Fat mass increases most, but lean mass, blood volume and organ size also increase, and cardiac output rises. How far a drug's volume changes depends on where the drug goes. Lipophilic drugs, which dissolve readily in fat, such as some benzodiazepines, can have a much larger volume in patients with obesity, so a loading dose based on ideal weight may be too small. Hydrophilic drugs, which stay mainly in water and lean tissue, such as aminoglycosides, have a volume that increases less than total weight, so a dose based on total weight may be too large (Hanley et al., 2010). The right weight for a loading dose is the weight that matches where the drug actually goes, and that is different for different drugs.

The distinction has a practical consequence that nurses see at the bedside. When a lipophilic sedative is given by continuous infusion to a patient with obesity, the drug moves steadily into fat tissue, which acts as a reservoir. After the infusion stops, the drug moves back out of fat into the blood over many hours, so the patient may stay sedated far longer than the drug's usual half-life would suggest. Nurses who expect a patient to wake within an hour of stopping a sedative, based on experience with leaner patients, may worry about a neurological problem, or may be tempted to give a reversal agent, when the delay is simply pharmacokinetic. The opposite problem occurs with hydrophilic drugs dosed on total weight: concentrations can be higher than intended, with more risk of toxicity, because the drug has less room to spread out than the patient's size suggests. Both errors come from the same mistake, assuming that a bigger body is simply a larger version of a smaller one.

Clearance and the Maintenance Dose

Clearance, the rate at which the body removes a drug, determines the maintenance dose needed to keep concentrations steady. Clearance does not rise in proportion to body weight. Kidney function often increases in obesity, but not in step with weight, and the effects on liver metabolism vary by pathway; the review by Hanley et al. (2010) describes increased activity of some liver enzymes and conjugation pathways but no single weight measure that predicts clearance for all drugs. Half-life depends on both volume and clearance, so a drug whose volume grows more than its clearance will take longer to eliminate in a patient with obesity, and it will also take longer to reach steady state and longer to leave the body after it is stopped.

The Weights in the Chart

Several weight measures appear in orders and pharmacy notes, and nurses need to recognize them. Total body weight is the measured weight. Ideal body weight is calculated from height and sex and approximates the weight of a person of that height without excess fat. Adjusted body weight adds a fraction of the difference between total and ideal weight to ideal weight, and is used for some drugs whose distribution extends partly into excess tissue. Lean body weight estimates fat-free mass. Each is used for different drugs, and the choice should come from the drug's properties and from guidance for that drug, not from habit. All of them except ideal body weight depend on an accurate measured total weight.

Worked Example: Vancomycin in a 150-Kilogram Patient

The patient is a composite 46-year-old woman, 165 cm tall with a measured weight of 150 kg and a body mass index of about 55, admitted with extensive cellulitis of the lower leg. Methicillin-resistant Staphylococcus aureus is suspected and vancomycin is ordered. Vancomycin is hydrophilic but its volume increases with body weight in obesity, and its clearance depends largely on kidney function. The current consensus guideline on vancomycin monitoring recommends that loading doses in patients with obesity be based on actual body weight, with an upper limit on any single dose, and that maintenance dosing be guided by estimating the patient's total drug exposure over 24 hours, the area under the concentration-time curve, rather than by trough levels alone (Rybak et al., 2020). Because standard population estimates of clearance fit poorly at extremes of weight, the guideline favors early measurement of levels to individualize the regimen.

For nurses, this plan has specific consequences. The loading dose will be large, and its infusion rate must be slow enough to avoid infusion reactions, so the infusion may take two to three hours. Blood samples for levels must be drawn at the times the pharmacist specifies, often two samples after one dose, because the exposure calculation depends on accurate timing; a sample drawn late or from the line through which the drug is infusing will produce a misleading result. And because clearance depends on kidney function, nurses must watch creatinine, urine output and other nephrotoxic drugs, as with the aminoglycosides discussed in Module 1.

Teaching Points for Nurses

The author's session on obesity pharmacokinetics for medical-surgical nurses rests on four points. First, weigh the patient on admission with an appropriate scale, and never enter a stated or estimated weight for a patient whose weight will drive dosing; if a bariatric scale is not available on the unit, the admission is not complete until one is found. Second, when an order says milligrams per kilogram, check which weight the pharmacist used and why, and ask if it is unclear. Third, expect larger loading doses and longer infusions for some drugs and plan the infusion time accordingly. Fourth, treat the timing of drug levels as part of the dose, because in patients whose pharmacokinetics are hard to predict, the levels are how the dose is corrected. Nurses will practice with three short cases, one each for a lipophilic drug, a hydrophilic drug and vancomycin, and will explain in each which weight fits and why.

References

Hales, C. M., Carroll, M. D., Fryar, C. D., & Ogden, C. L. (2020). Prevalence of obesity and severe obesity among adults: United States, 2017-2018 (NCHS Data Brief No. 360). National Center for Health Statistics.

Hanley, M. J., Abernethy, D. R., & Greenblatt, D. J. (2010). Effect of obesity on the pharmacokinetics of drugs in humans. Clinical Pharmacokinetics, 49(2), 71-87. https://doi.org/10.2165/11318100-000000000-00000

Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., Rodvold, K. A., Maples, H. D., & Lomaestro, B. M. (2020). Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy, 77(11), 835-864. https://doi.org/10.1093/ajhp/zxaa036